Novartis AG Total Assets 2006-2020 | NVS

Novartis AG total assets from 2006 to 2020. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Novartis AG total assets for the quarter ending June 30, 2020 were $123.763B, a 6.42% increase year-over-year.
  • Novartis AG total assets for 2019 were $118.37B, a 18.68% decline from 2018.
  • Novartis AG total assets for 2018 were $145.563B, a 9.38% increase from 2017.
  • Novartis AG total assets for 2017 were $133.079B, a 2.27% increase from 2016.
Novartis AG Annual Total Assets
(Millions of US $)
2019 $118,370
2018 $145,563
2017 $133,079
2016 $130,124
2015 $131,556
2014 $125,387
2013 $126,254
2012 $124,191
2011 $117,496
2010 $123,318
2009 $95,505
2008 $78,299
2007 $75,452
2006 $68,008
2005 $57,732
Novartis AG Quarterly Total Assets
(Millions of US $)
2020-06-30 $123,763
2020-03-31 $123,097
2019-12-31 $118,370
2019-09-30 $115,971
2019-06-30 $116,294
2019-03-31 $137,946
2018-12-31 $145,563
2018-09-30 $142,994
2018-06-30 $142,058
2018-03-31 $135,524
2017-12-31 $133,079
2017-09-30 $134,972
2017-06-30 $133,749
2017-03-31 $131,986
2016-12-31 $130,124
2016-09-30 $134,007
2016-06-30 $131,436
2016-03-31 $132,448
2015-12-31 $131,556
2015-09-30 $132,927
2015-06-30 $135,413
2015-03-31 $134,935
2014-12-31 $125,387
2014-09-30 $125,377
2014-06-30 $125,768
2014-03-31 $125,332
2013-12-31 $126,254
2013-09-30 $124,594
2013-06-30 $121,072
2013-03-31 $121,011
2012-12-31 $124,191
2012-09-30 $121,219
2012-06-30 $118,492
2012-03-31 $119,411
2011-12-31 $117,496
2011-09-30 $121,377
2011-06-30 $125,915
2011-03-31 $127,218
2010-12-31 $123,318
2010-09-30 $124,628
2010-06-30 $96,924
2010-03-31 $95,795
2009-12-31 $95,505
2009-09-30 $90,686
2009-06-30 $84,274
2009-03-31 $77,970
2008-12-31 $78,299
2008-09-30 $82,020
2008-06-30 $83,399
2008-03-31 $76,318
2007-12-31 $75,452
2007-09-30 $76,936
2007-06-30 $70,621
2007-03-31 $68,324
2006-12-31 $68,008
2006-09-30 $66,862
2006-06-30 $65,929
2006-03-31 $58,848
2005-12-31 $57,732
2005-09-30 $54,670
2005-06-30 $53,043
2005-03-31 $49,646
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $189.756B $47.498B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $391.238B 18.65
Roche Holding AG (RHHBY) Switzerland $294.553B 0.00
Pfizer (PFE) United States $213.662B 13.35
Merck (MRK) United States $204.919B 14.63
AbbVie (ABBV) United States $163.988B 9.99
Novo Nordisk (NVO) Denmark $152.214B 24.77
Eli Lilly (LLY) United States $146.273B 22.33
AstraZeneca (AZN) United Kingdom $145.417B 28.27
Sanofi (SNY) $128.988B 15.33
GlaxoSmithKline (GSK) United Kingdom $102.323B 13.42
Bayer (BAYRY) Germany $61.403B 8.85
H Lundbeck (HLUYY) Denmark $7.388B 0.00
Innoviva (INVA) United States $1.370B 6.56